Epigenomics, together with its partner Affymetrix, developed a new Differential Methylation Hybridization (DMH) microarray for highly efficient methylation profiling of human samples. Differentially methylated fragments can be further explored and developed into biomarkers for multiple applications.

• Covers over 50,000 genomic fragments.
• Provides highly reproducible, reliable results.
• Requires only 1 µg of DNA.
• Marker candidates readily transfer to assay technologies suitable for clinical routine.

DMH methylation profiling is available from Epigenomics as part of its Biomarker Service offerings.

References:
Huang, T., et al., (1999), Methylation profiling of CpG islands in human breast cancer cells, Hum. Mol. Genet. 8, 459-470.

U.S. Patent No. 6,605,432.

Example Data

Quantification of methylated DNA by DMH

Artificially methylated DNA (0%, 50%, 100%) was analyzed using Epigenomics' DMH micorarray. More than 90% of all probe sets differentiate well between the different methylation states.

Reproducibility of DMH results

Two DMH workflows (incl. DNA preparation, pre-analytics and chip hybridization) were repeated and plotted against each other. Epigenomics' DMH process is extremely reproducible